Projo Biz Blog

Cumberland-based Collegium Pharmaceutical, Inc., a specialty pharmaceutical developer, said the U.S. Food and Drug Administration has approved the nasal spray the company developed.

The spray is an aqueous-based steroid for once daily treatment of symptoms associated with both seasonal and perennial allergic rhinitis in adults and children 12 years of age and older.

The new product will compete in the approximately $2.5 billion-a-year U.S. market for nasal-inhaled steroids for the treatment of allergic rhinitis.

 Tags  Collegium Pharmaceutical nasal spray U.S. Food and Drug Administration

Leave a comment

Name:

Email:

URL:  

Remember personal info?

Captcha:

Type the characters you see in the picture above.